Side effects & safety

GLP-1 medications and alcohol

Evidence-sourced

Written and fact-checked to our published editorial standards.Last updated 2026-08-05. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Moderate

Two different questions are hiding in this one. The first is whether these medications change how much you want to drink — and many people report that they do, an effect that has now been tested in a randomised trial rather than resting on anecdote. The second is whether it is safe for you to drink while taking one, which depends on what else you take and is a question for your prescriber. No GLP-1 medication is approved to treat alcohol use disorder.

Key takeaways

Reduced interest in alcohol is a widely reported effect, and it has been studied in a randomised trial.
It is not an approved use. No product carries an indication for alcohol use disorder.
Nothing here is a reason to start a GLP-1, or to stop treatment you are already receiving for drinking.
Whether you can safely drink is a separate question that turns on your other medications.

Important limitation: We are not publishing effect sizes. The trial evidence is early, the population studies are observational, and the figures circulating from them are exactly the kind that should not be repeated second-hand. What we can say is that the effect has been tested rather than merely noticed.

Next action: If you are drinking in a way that worries you, that is worth raising directly — there are treatments approved for it, which a GLP-1 is not. If you simply want to know whether a drink is safe alongside your prescription, ask the prescriber who wrote it.

Primary sources: JAMA Psychiatry (Hendershot et al.), PubMed 39937469, PubMed Central (PMC12663662), National Institutes of Health

General education, not medical advice. Nothing here is a recommendation to start, stop, or change any medication, or to change how you drink.

The effect people notice

It comes up constantly and it did not start with researchers. People taking these medications for weight or diabetes began reporting, unprompted, that alcohol had lost some of its appeal — that they forgot to finish a drink, or stopped wanting the second one.

What makes this more than a curiosity is that it has moved from anecdote into trial. A randomised, placebo-controlled trial of once-weekly semaglutide in adults with alcohol use disorder reported reductions in craving and in the amount consumed, and NIH has reported on research adding a weekly GLP-1 to cognitive behavioural therapy. A systematic review has since pooled the evidence across studies. This is an active field, not a rumour.

The effect has been tested rather than merely noticed. That is a real change in status — and it is still a long way from being something you can be prescribed for.

What that does not mean

It is not an approved treatment. No GLP-1 receptor agonist carries an indication for alcohol use disorder. Prescribing one for that purpose is off-label, and a prescriber may reasonably decline.
It is not a reason to start one. These are medications with real side effects, taken long-term, for approved conditions — see what those side effects are.
It is not a substitute for treatment that works. There are medications approved for alcohol use disorder and there is therapy with evidence behind it. A promising off-label finding does not displace either.
It is not a prediction about you. A trial result describes a group average. Plenty of people notice no change at all.

Why we are not giving you the numbers

You will find pages quoting striking percentages — large reductions in relapse risk, or in new diagnoses. Most trace back to observational database studies, where the design cannot separate the drug’s effect from the reasons people were prescribed it in the first place. We have not been able to read those papers directly, and repeating their headline figures on a page like this would give them a confidence the studies themselves do not claim.

So this page reports the direction and the status of the evidence, and leaves the magnitudes to the publications listed at the foot. That is the same discipline applied on our statistics page, where figures we could not verify are named as absent rather than estimated.

The other question: can you drink while taking one?

This is the practical question, and it is genuinely individual. Two things make it worth asking rather than assuming:

The gastrointestinal effects. These medications slow gastric emptying, and nausea is the most common adverse effect in the class. Alcohol is an irritant on its own. Whether the combination is tolerable is something people find out individually, and the titration weeks are when side effects usually spike — see dosing and titration.
Blood sugar, if that is why you are taking it. Alcohol affects glucose regulation, and if your GLP-1 is prescribed for type 2 diabetes alongside other glucose lowering medication, that interaction belongs in a conversation with your prescriber rather than a web page.

When this stops being a lifestyle question

If you are drinking in a way that concerns you, or that you have tried to change without success, that is worth raising with a clinician in its own right — not as a footnote to a weight-loss medication.
Do not stop an existing treatment for alcohol use on the strength of starting a GLP-1. Nothing in the current evidence supports that, and the approved treatments have far more behind them.
Severe or persistent vomiting is a reason to contact your prescriber whatever caused it — see side effects and red flags.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

Once-weekly semaglutide in adults with alcohol use disorder: a randomised clinical trialJAMA Psychiatry (Hendershot et al.), PubMed 39937469Supports: That the effect on drinking has been tested in a randomised, placebo-controlled trial, which reported reductions in craving and in alcohol consumed.
Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysisPubMed Central (PMC12663662)Supports: That the finding has been synthesised across studies rather than resting on a single trial.
Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinkingNational Institutes of HealthSupports: NIH's own reporting of the research programme, and that this remains an area of active investigation rather than settled practice.
Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status: no GLP-1 receptor agonist is approved to treat alcohol use disorder, so any such use is off-label.
FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved indications and labelled adverse reactions for each product discussed.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.